Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information (2552.HK)

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Our Science

> Our Science

> Poster and Presentation

Poster and Presentation

Peer Reviewed Publications

A Novel Dual Pancreatic and Hepatic Acting Glucokinase Activator, HMS5552: Phase I Studies in Healthy Subjects and T2DM Patients

2015 ADA Poster

Hua Medicine

Jun 05, 2015

7259

Online link unavailable, presentation available upon request. (BD@eladfund.com)

Return list

Clinically Differentiated Glucokinase Activator HMS5552: Effective Control of 24-Hour Glucose and Improvement of β Cell Function in T2DM Patients

Fragile X syndrome as a rare disease in China - Therapeutic challenges and opportunities.

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.